Humane Genomics
A platform to make artificial viruses as cancer therapeutics.
Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.
- Website
- humanegenomics.com
- City
- New York City
- Country
- United States
- YC batch
- Summer 2021
- Team
- 5 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in New York City
Ro$5bn
Health technology. Valued at $5bn (March 2021).
Noom$3.7bn
Healthcare. Valued at $3.7bn (May 2021).
Headway$2.3bn
Healthcare. Valued at $2.3bn (July 2024).
Sword Health$2bn
Health. Valued at $2bn (November 2021).
H1
Connecting stakeholders across the healthcare ecosystem.
Opentrons
We make robots for biologists.
Claim this profile
Free and instant: prove you run humanegenomics.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Humane Genomics across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Humane Genomics's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
